ConcertAI’s TeraRecon Offers New Suite to Eureka Clinical AI Platform
Cardio Suite to reportedly provide clinicians with artificial intelligence technology to help fight cardiovascular disease.
ConcertAI’s TeraRecon, a clinical AI SaaS company, broke the news that its Eureka Clinical AI platform's Cardio Suite now provides clinicians with the artificial intelligence and deep learning technology necessary to help identify, treat, and manage cardiovascular disease.
"The Cardio Suite represents our second installment of dedicated care area suites following the launch of the Neuro Suite earlier this year," said Dan McSweeney, President, TeraRecon. "We are committed to supporting cardiologists and clinicians by bringing novel AI powered solutions, such as our Cardio Suite, forward to more efficiently help physicians screen and diagnose cardiac disease patients so that appropriate treatments can be delivered."
Reference: ConcertAI's TeraRecon Adds Cardio Suite to its Eureka Clinical AI Platform. PR Newswire. August 30, 2023. Accessed September 5, 2023. https://www.prnewswire.com/news-releases/concertais-terarecon-adds-cardio-suite-to-its-eureka-clinical-ai-platform-301912876.html
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
